Buy Rating Reaffirmed for Nurix Therapeutics: Promising Clinical Data and Increased Approval Probability for NX-5948
Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) and increased the price target ...
Optimistic Buy Rating for Nurix Therapeutics’ NX-5948 Driven by Strong Efficacy in CLL and Strategic Expansion Plans
Analyst Gil Blum from Needham reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price target at ...
Pharmabiz19d
EMA grants PRIME designation to Nurix Therapeutics’ NX-5948 to treat relapsed or refractory chronic lymphocytic leukaemia
“PRIME designation for NX-5948 is an important recognition of the unmet patient need in CLL, particularly in the growing number of patients whose cancer has progressed following BTK inhibitor and BCL2 ...
Nasdaq21d
Nurix Therapeutics announces PRIME designation for NX-5948 from EMA
Nurix Therapeutics (NRIX) announced that the European Medicines Agency, or EMA, has granted PRIME designation for NX-5948, a highly selective degrader of Bruton’s tyrosine kinase, for the ...
abc2724d
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
NX-5948 is Nurix’s proprietary, orally available, brain penetrant Bruton’s tyrosine kinase (BTK) degrader, which is being developed for the potential treatment of inflammation and autoimmune ...
Stockhouse25d
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
NX-5948 is Nurix’s proprietary, orally available, brain penetrant Bruton’s tyrosine kinase (BTK) degrader, which is being developed for the potential treatment of ...